

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

SECTION 1. IDENTIFICATION

Product name : Montelukast Tablet Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
 Address : 30 Hudson Street, 33rd floor
 Jersey City, New Jersey, U.S.A 07302
 Telephone : 551-430-6000
 Emergency telephone : 215-631-6999
 E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical


SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Carcinogenicity (Inhalation) : Category 2

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
 H351 Suspected of causing cancer if inhaled.

Precautionary Statements : **Prevention:**
 P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read and understood.
 P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response:
 P308 + P313 IF exposed or concerned: Get medical attention.
Storage:
 P405 Store locked up.
Disposal:
 P501 Dispose of contents and container to an approved waste disposal plant.

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	$\geq 30 - < 50$
Montelukast	151767-02-1	$\geq 5 - < 10$
Magnesium stearate	557-04-0	$\geq 1 - < 5$
Titanium dioxide	13463-67-7	$\geq 0.1 - < 1$

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of causing cancer if inhaled.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use.

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Montelukast	151767-02-1	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
Titanium dioxide	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : tablet

Color : colored

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Montelukast Tablet Formulation

Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Montelukast Tablet Formulation

Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

Components:**Montelukast:**

Species : Rabbit
Result : Mild skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Montelukast:**

Species : Rabbit
Result : Severe irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Montelukast:**

Remarks : No data available

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

Result : negative
 Remarks : Based on data from similar materials

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
 Routes of exposure : Skin contact
 Species : Mouse
 Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster fibroblasts
 Result: negative
 Test Type: Chromosomal aberration
 Test system: Chinese hamster ovary cells
 Result: negative
 Test Type: Alkaline elution assay
 Test system: rat hepatocytes
 Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
 Species: Mouse
 Cell type: Bone marrow
 Application Route: Oral
 Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
 Species: Mouse
 Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:**Cellulose:**

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Montelukast:

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Species : Mouse
 Application Route : Oral
 Exposure time : 92 weeks
 Result : negative

Titanium dioxide:

Species : Rat
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 Years
 Method : OECD Test Guideline 453
 Result : positive
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

IARC Group 2B: Possibly carcinogenic to humans
Titanium dioxide 13463-67-7

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Montelukast:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL: 200 mg/kg body weight
Symptoms: Reduced fertility

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 100 mg/kg body weight
Symptoms: Reduced fertility

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Montelukast Tablet Formulation

Version Revision Date: SDS Number: Date of last issue: 03/23/2020
7.3 10/02/2020 23093-00017 Date of first issue: 10/17/2014

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Montelukast:

Species : Monkey, male and female
NOAEL : 150 - 300 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rat
NOAEL : 24,000 mg/kg
Application Route : Ingestion

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

Exposure time : 28 Days
Species : Rat
NOAEL : 10 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Montelukast:

Skin contact : Remarks: May irritate skin.
Eye contact : Symptoms: Severe irritation
Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,
Headache, Cough, Abdominal pain, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Montelukast:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Montelukast Tablet Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210
 Remarks: No toxicity at the limit of solubility.
- NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l
 Exposure time: 7 d
 Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.23 mg/l
 Exposure time: 21 d
 Remarks: No toxicity at the limit of solubility.
- Toxicity to microorganisms : EC50: > 100 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility.

Magnesium stearate:

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
 Exposure time: 48 h
 Method: DIN 38412
 Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
 Exposure time: 47 h
 Test substance: Water Accommodated Fraction
 Method: Directive 67/548/EEC, Annex V, C.2.
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
 Exposure time: 16 h
 Test substance: Water Accommodated Fraction
 Remarks: Based on data from similar materials

Titanium dioxide:

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Montelukast:

Biodegradability : Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

Magnesium stearate:

Biodegradability : Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Montelukast:

Partition coefficient: n-octanol/water : log Pow: > 4.3

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version Revision Date: SDS Number: Date of last issue: 03/23/2020
7.3 10/02/2020 23093-00017 Date of first issue: 10/17/2014

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Carcinogenicity

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-mannitol	69-65-8
Cellulose	9004-34-6
D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate	64044-51-5
Montelukast	151767-02-1
Croscarmellose sodium	74811-65-7

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version 7.3 Revision Date: 10/02/2020 SDS Number: 23093-00017 Date of last issue: 03/23/2020
Date of first issue: 10/17/2014

Hydroxypropyl cellulose

9004-64-2

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

Cellulose

9004-34-6

Magnesium stearate

557-04-0

The ingredients of this product are reported in the following inventories:

AICS : not determined


DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	*	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA : 8-hour, time-weighted average
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA : 8-hour time weighted average

SAFETY DATA SHEET



Montelukast Tablet Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 03/23/2020
7.3	10/02/2020	23093-00017	Date of first issue: 10/17/2014

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 10/02/2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8